AI Labs
Tempus AI
30-Second Executive Brief
Executive Assessment
Tempus AI functions as a regional institution within AI Labs, backed by 75% sourcing coverage, with a stable competitive position.
- Maintains 2 mapped relationships across the graph
- 75% sourcing coverage across sourced relationships
- Tracked as regional institution within the AI Labs category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 75%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Insufficient Data
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A precision medicine company applying AI to genomic sequencing and clinical data, combining diagnostics and data-licensing businesses to accelerate oncology treatment decisions and drug development. Tempus AI reported Q1 2026 revenue of $348.1 million (up 36.1% year-over-year), with Diagnostics revenue of $261.1 million (driven by 28% oncology volume growth); minimal residual disease test volume reached approximately 6,500 tests in Q1 2026, up roughly 500% year-over-year.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by Recursion Pharmaceuticals
“all actions and anticipated performance under the Tempus Agreement and the Restated Agreement”
SEC 8-K exhibit (0001601830-26-000097) · Aug 5, 2026
Mentions Merck & Co.
“Established a multi-year, strategic collaboration with Merck to accelerate biomarker discovery and development by leveraging Tempus' multimodal data and Lens analytical platform.”
SEC 8-K exhibit (0001193125-26-206317) · May 5, 2026
Mentions Gilead Sciences
“Expanded our collaboration with Gilead to provide enterprise-wide access to our AI-driven Lens platform and multimodal datasets, aimed at advancing their oncology pipeline through real-world evidence and AI-driven insights.”
SEC 8-K exhibit (0001193125-26-206317) · May 5, 2026
Mentions Medtronic
“Announced study results from the ALERT trial in collaboration with Medtronic showing that Tempus' AI-driven EHR notifications increased life-saving heart valve procedures by 40% for patients with significant disease.”
SEC 8-K exhibit (0001193125-26-206317) · May 5, 2026
Mentions AstraZeneca
“Successfully delivered our first oncology foundation model to AstraZeneca”
SEC 8-K exhibit (0001193125-26-326083) · Jul 30, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources · 1 government/SEC filing
- Tempus AI Q1 2026 earnings release — Tempus AI Q1 2026 revenue up 36% to $348M, raises full-year guidance to $1.6Bmarket-data
- U.S. Securities and Exchange Commission (EDGAR) — Tempus AI FY2025 Annual Report (Form 10-K), filed with the SECgovernment
- Tempus AI Q1 2026 earnings coverage (Tickeron) — Tempus AI's MRD cancer-monitoring test volume surges roughly 500% year-over-year in Q1 2026market-data
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Tempus AI — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
A 500% MRD volume jump is measured against a very small starting base
22% confidenceTempus AI's minimal residual disease (MRD) test volume reached approximately 6,500 tests in Q1 2026, up roughly 500% year-over-year, as the company raised full-year 2026 revenue guidance to $1.59-1.60 billion.
This is InsightNodes' own interpretive read: Tempus AI's minimal residual disease test volume growing roughly 500% year-over-year to about 6,500 tests in a quarter is a strong adoption signal, but the small absolute base means the percentage figure is likely to normalize as volume scales. The more durable indicator of MRD traction will be sequential quarter-over-quarter volume once the year-over-year comparison stops being against an early-stage base.
Tempus AI Q1 2026 earnings coverage (Tickeron) · Aug 14, 2026